Credit Suisse gets bullish on Baxter

Credit Suisse upgrades Baxter (BAX) to Outperform from Neutral.

The move comes on the heels of the company's pacritinib deal with Cell Therapeutics.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs